BioSpace News Archive

Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.

Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.

The Media and Innovation Lab at the University of Miami is developing digital twins of patients in an effort to bring robust healthcare to underserved communities.

Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.

Two former executives of JHL Biotech were sentenced to a year and one day each in prison after being found guilty of conspiracy and fraud.

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced it has received notification from the U.S. Food and Drug Administration (“FDA”) that the FDA’s Clinical Hold on AIM’s investigational new drug (“IND”) application for a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (AMP-270) has been lifted and the Company may proceed with the study.

CareDx, Inc. announced that it will hold a virtual “Xenotransplantation Innovation Day” featuring a leading panel of transplant experts who will share the latest advancements in xenotransplantation after genetically modified pig kidneys and, separately, a pig heart were recently successfully transplanted, two medical firsts.

Todos Medical, Ltd. announced it has completed the acquisition of all 3CL protease biology-related assets and formed a majority-owned subsidiary called 3CL Pharma Ltd. 3CL Pharma will focus on developing therapeutics, diagnostics and dietary supplements based on 3CL protease biology related work of Dr. Dorit Arad, who joins Todos Medical as the newly appointed Chief Scientific Officer.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced longer-term data from the Phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab.